News and Media

Next Gen CAR-T Platform a Potential Game Changer – Independent Investment Research

PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) ...
Read More
| News

Next Gen CAR-T Platform a Potential Game Changer – Independent Investment Research

PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) ...
Read More
| News

Prescient Therapeutics has path forward as they look to future of cancer treatments

Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the ...
Read More
| News

Momentum builds for small cap biotechs

Capital dedicated by local investors to risky investments that was once largely tied up in junior explorers is starting to ...
Read More
| News

Prescient ushers in “next gen” immunotherapy cancer platform

ASX listed biotech company Prescient Therapeutics (ASX: PTX) has this week unveiled two significant licence agreements that forms the IP ...
Read More
| News

Receive Email Updates

To stay fully updated on Prescient Therapeutics Corporate Activity and Company Announcements, please subscribe for up to the minute updates

WEBCAST AND MEDIA

PTX Investor Briefing - 28 January

PTX CEO Steven Yatomi Clarke discusses Prescient Therapeutics treatments in detail

Follow us and stay connected